*BIKTARVY® should not be co-administered simultaneously with antacids, oral medications or supplements containing magnesium, aluminium or iron under fasted conditions. BIKTARVY® should be administered at least 2 hours before, or with food 2 hours after antacids, oral medications or supplements containing magnesium and/or aluminium.  BIKTARVY® should be administered at least 2 hours before iron supplements, or taken together with food at any time. In pregnant patients, dosage adjustments are recommended for co-administration of polyvalent cation-containing antacids, oral medications or supplements (including calcium-containing oral medications or supplements). See SmPC for full information, including use during pregnancy.^1,2

†In patients with moderate renal impairment, close monitoring should be considered when starting co-administration of BIKTARVY® with metformin, in line with the metformin SmPC.

Nephrotoxicity: Post-marketing cases of renal impairment, including acute renal failure and proximal renal tubulopathy (PRT) reported with TAF-containing products. A potential risk of nephrotoxicity resulting from chronic exposure low tenofovir exposure with TAF cannot be excluded. It is recommended that renal function is assessed prior to, or when initiating, TAF and is monitored during therapy in all patients as clinically appropriate. If clinically significant decreases in renal function, or evidence of PRT occur, consider discontinuation of TAF.